The aim: To analyze and calculate CVR in patients with T2DM and concomitant obesity. Materials and methods: The selection of patients was carried out based on the Uzhhorod District Clinical Hospital, in the period from November 2016 to January 2020. All patients were divided into 3 groups: 1 (n=93) with T2DM and concomitant obesity, 2 (n=87) with T2DM, 3 (n=39) with obesity. The treatment period lasted 1 year and included dosed exercise for at least 30 minutes per day and dietary recommendations. Patients in groups 1 and 2 received metformin 850 mg twice daily in combination with dapagliflozin 10 mg once daily. CVR was determined at the time of enrollment and after 1 year of treatment using: American College of Cardiology / American Heart Association Guideline on the Assessment of Cardiovascular Risk (2013) (ASCVD Risk) and Framingham Risk Score (FRS). Results: The data obtained as a result of the study revealed the highest CVR in patients of group 1, in contrast to group 2 and 3 (p<0.05). After 1 year of complex treatment, CVR indicators were statistically significantly reduced in all experimental groups (p<0.05). Conclusions: Determining CVR parameters and exposure to them within 10 years can remove unwanted cardiovascular complications.
The aim: To analyze the relationship between non-alcoholic fatty liver disease and changes in the gut microbiota. Materials and methods: The publications of domestic and foreign editions in the databases of the United European Gastroenterology (UEG) Journal, PubMed, MEDLINE, Web of Science were processed and analyzed. Conclusions: In recent years, non-alcoholic fatty liver disease was placed among the important diseases in gastroenterology. During this time, more and more data appear on the link between changes in the human intestinal microbiome and the development of metabolic diseases, including NAFLD. Contemporary research has indeed found evidence of such a relationship. Thus, some strains of microorganisms have been identified in more detail, which directly or indirectly affect the development or course of the above-mentioned disease. For a better understanding of the strategies for the treatment of pathologies, it is necessary to delve into the study of etiological factors, therefore, NAFLC cannot be considered a pathology that has been sufficiently studied. Indeed, recent data indicate that the development and severity of the course of the disease are not always associated with the physiological processes already known to us.
The aim: To study intermittent fasting (IF) treatment in patients with non-alcoholic fatty liver disease (NAFLD) and prediabetes. Materials and methods: Patients with NAFLD (n=95) were examined. The patients were divided into 2 groups: Group 1 – NAFLD with obesity, Group 2 – NAFLD and prediabetes. All patients in both groups had Body mass index (BMI) within the 2nd degree of obesity range (30.0 kg/m2 to 34.5 kg/m2). Results: The effect of IF on anthropometric parameters, carbohydrate and lipid levels in patients with NAFLD with obesity and NAFLD with prediabetes, 6 and 12 months after treatment is shown. Conclusions: Intermittent fasting has a statistically significant effect on anthropometric parameters in NAFLD with obesity and NAFLD with prediabetes. Metformin administration after intermittent fasting in 12 months showed a statistically significant improvement in lipid and carbohydrate profiles.
The aim: Evaluate clinical and laboratory parameters of the patients with type 2 diabetes mellitus and concomitant obesity after a course of dapagliflozin treatment and compare with a standard treatment regimen. Materials and methods: Conducted a comprehensive clinical laboratory examination and measurement of the anthropometric parameters of the patients with type 2 diabetes mellitus and concomitant obesity, with subsequent statistical calculations. Results: The data obtained at different stages of the study revealed a statistically significant effect of glucose treatment and glycosylated hemoglobin (HbA1c). Since the 6th month of dapagliflozin treatment, we have shown a tendency to lose weight compared to baseline in this group of patients and controls. Conclusions: Type 2 diabetes mellitus and obesity significantly increase the risk of developing a number of complications. Complex control and effects on clinical laboratory and anthropometric parameters can statistically significantly influence the development of the complications, and in this context, dapaglifloflozin showed statistically better results than standard metformin monotherapy.
The aim: Determine the most common non-communicable diseases which are associated with an increased rate of moderate and severe COVID-19 infection. Identify the best tools for diagnosing COVID-19 and predicting the deterioration of the disease. Materials and methods: Publications were processed and analyzed according to the keywords of the topic of work “COVID-19”, “non-communicable disease”, “obesity”, “hypertension”, “Comorbidities”, “frailty”, “diabetes”, “chronic obstructive pulmonary disease”, “cardio-vascular diseases”, “liver diseases”, “diagnostic tools”, “outcomes” in the databases of PubMed, MEDLINE, Web of Science. Conclusions: As a result of the analysis, we found that patients with concomitant obesity, diabetes mellitus, COPD, CVD and liver diseases have an increased the risk of severe forms and death from COVID-19.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.